Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Main Composition
AVTX Avalo Therapeutics
5.460
+0.140+2.63%
All
YOY
Do not show
Business Unit:USD
nameYOYOperating income%
Product revenue, net--4.77M88.42%
License revenue--625K11.58%
Region Unit:USD
nameYOYOperating income%
United States--5.4M100.00%
Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist